RCE Stock Overview
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Recce Pharmaceuticals Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.52 |
| 52 Week High | AU$0.69 |
| 52 Week Low | AU$0.40 |
| Beta | 1.05 |
| 11 Month Change | 5.05% |
| 3 Month Change | 10.64% |
| 1 Year Change | 14.29% |
| 33 Year Change | -43.78% |
| 5 Year Change | 89.09% |
| Change since IPO | 67.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| RCE | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 0.1% |
| 1Y | 14.3% | 91.9% | 18.3% |
Return vs Industry: RCE underperformed the Australian Pharmaceuticals industry which returned 91.9% over the past year.
Return vs Market: RCE underperformed the Australian Market which returned 18.3% over the past year.
Price Volatility
| RCE volatility | |
|---|---|
| RCE Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: RCE has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: RCE's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | James Graham | www.recce.com.au |
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. Its lead candidate is RECCE 327 (R327) for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use.
Recce Pharmaceuticals Ltd Fundamentals Summary
| RCE fundamental statistics | |
|---|---|
| Market cap | AU$120.44m |
| Earnings (TTM) | -AU$17.66m |
| Revenue (TTM) | AU$5.03m |
24.0x
P/S Ratio-6.8x
P/E RatioIs RCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RCE income statement (TTM) | |
|---|---|
| Revenue | AU$5.03m |
| Cost of Revenue | AU$7.22m |
| Gross Profit | -AU$2.19m |
| Other Expenses | AU$15.47m |
| Earnings | -AU$17.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.076 |
| Gross Margin | -43.52% |
| Net Profit Margin | -351.24% |
| Debt/Equity Ratio | -101.7% |
How did RCE perform over the long term?
See historical performance and comparison